Nevro Corp Stock News

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

Nevro Corp. shares have significantly underperformed, selling 57% lower than in 2021. The company's top-line momentum continues, but it faces economic challenges and lacks value creation for sharehold

Nevro's (NVRO) HFX Connect system is expected to treat individual patients per their requirements with 35 pre-programmed customizable plans.

Nevro said it expects third-quarter revenue to fall between 4% to 6% year over year. The company is reorganizing its sales force.

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the second quarter owing to robust domestic and international performances.

Nevro Corp. (NYSE:NVRO ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group LLC Kevin Thornal - President and CEO Rod MacLeod - Chief Fina

Nevro (NVRO) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.71 per share a year ago.

Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.

Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficient marketing, and internationalization efforts cou

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.

Nevro Corp. (NVRO) Q1 2023 Earnings Call Transcript.

Nevro (NVRO) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $0.98 per share a year ago.

The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Nevro (NVRO). While the effectiveness of this highly sought-after metric is questionable, the positive

Today Nevro announced the appointment of a new CEO/president along with its preliminary 2023 Q1 financial results. With a possible recession looming, investors are exiting the cash-flow-negative medte

Nevro (NYSE:NVRO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 3 1 0 Last 30D 0 0 1 0